膝下慢性威胁性肢体缺血的血管重建结局:系统综述与荟萃分析
该系统综述与荟萃分析纳入44项前瞻性研究、8602例膝下慢性威胁性肢体缺血(CLTI)患者,评估不同血管重建方式的结局。围术期结局各方式相似;大隐静脉旁路通畅率最高,人工血管旁路至膝下靶血管的截肢和通畅结局明显较差;药物洗脱支架在膝下动脉通畅率优于裸金属支架,与球囊扩张相近。总体证据质量低。
要点
- 围术期(30天)死亡、截肢和主要不良心脏事件在各血管重建方式间大致相似。
- 大隐静脉旁路1年和2年一期通畅率分别为87%和78%,二期通畅率分别为94%和87%。
- 膝下动脉药物洗脱支架1年一期通畅率73%,优于裸金属支架的50%,与球囊扩张的66%相近。
核心结论
- CLTI膝下血管重建的现有证据存在重大局限,尤其对内血管方式治疗严重解剖模式病变的指导不足。
- 围术期死亡、截肢和主要不良心脏事件在各治疗方式间大致相似。
- 大隐静脉旁路通畅率最高,人工血管旁路至膝下靶血管的通畅和保肢结局明显较差。
研究设计与样本
- 系统综述与荟萃分析,检索多个数据库至2017年5月7日。
- 纳入至少1年随访、评估成人CLTI膝下血管重建患者相关结局的前瞻性研究。
- 共纳入44项研究,8602例患者;采用随机效应荟萃分析合并结局。
主要发现
- 膝下病变患者大隐静脉旁路1年和2年一期通畅率分别为87%和78%,二期通畅率分别为94%和87%,优于所有其他干预。
- 人工血管旁路在截肢和通畅结局方面明显劣于静脉旁路,尤其对膝下靶血管2年及以后。
- 膝下动脉药物洗脱支架1年一期通畅率73%,优于裸金属支架的50%,与球囊扩张的66%至少相当。
- 内血管干预与静脉旁路在2年生存、大截肢和无截肢生存方面大致相似,人工血管旁路肢体丢失率更高。
- 纳入研究总体为中至高偏倚风险,证据质量低。
临床怎么用
- 决策时应优先考虑大隐静脉旁路以获得最佳通畅率,尤其膝下靶血管。
- 避免将人工血管旁路用于膝下靶血管,因其通畅和保肢结局明显较差。
- 膝下局灶性病变可考虑药物洗脱支架或球囊扩张,两者通畅率相近。
- 现有证据质量低,临床决策需结合肢体严重程度和解剖分期个体化判断。
局限性
- 纳入研究总体为中等至高度偏倚风险,证据质量低。
- 缺乏比较性试验,日常决策常基于低质量证据。
- 无研究纳入长段胫动脉病变。
- 患者风险、肢体威胁严重程度和解剖结构异质性大,直接比较困难。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal strategy for revascularization in infrainguinal chronic limb-threatening ischemia (CLTI) remains debatable. Comparative trials are scarce, and daily decisions are often made using anecdotal or low-quality evidence. METHODS: We searched multiple databases through May 7, 2017, for prospective studies with at least 1-year follow-up that evaluated patient-relevant outcomes of infrainguinal revascularization procedures in adults with CLTI. Independent pairs of reviewers selected articles and extracted data. Random-effects meta-analysis was used to pool outcomes across studies. RESULTS: We included 44 studies that enrolled 8602 patients. Periprocedural outcomes (mortality, amputation, major adverse cardiac events) were similar across treatment modalities. Overall, patients with infrapopliteal disease had higher patency rates of great saphenous vein graft at 1 and 2 years (primary: 87%, 78%; secondary: 94%, 87%, respectively) compared with all other interventions. Prosthetic bypass outcomes were notably inferior to vein bypass in terms of amputation and patency outcomes, especially for below knee targets at 2 years and beyond. Drug-eluting stents demonstrated improved patency over bare-metal stents in infrapopliteal arteries (primary patency: 73% vs 50% at 1 year), and was at least comparable to balloon angioplasty (66% primary patency). Survival, major amputation, and amputation-free survival at 2 years were broadly similar between endovascular interventions and vein bypass, with prosthetic bypass having higher rates of limb loss. Overall, the included studies were at moderate to high risk of bias and the quality of evidence was low. CONCLUSIONS: There are major limitations in the current state of evidence guiding treatment decisions in CLTI, particularly for severe anatomic patterns of disease treated via endovascular means. Periprocedural (30-day) mortality, amputation, and major adverse cardiac events are broadly similar across modalities. Patency rates are highest for saphenous vein bypass, whereas both patency and limb salvage are markedly inferior for prosthetic grafting to below the knee targets. Among endovascular interventions, percutaneous transluminal angioplasty and drug-eluting stents appear comparable for focal infrapopliteal disease, although no studies included long segment tibial lesions. Heterogeneity in patient risk, severity of limb threat, and anatomy treated renders direct comparison of outcomes from the current literature challenging. Future studies should incorporate both limb severity and anatomic staging to best guide clinical decision making in CLTI.
引用
- Almasri J, Adusumalli J, Asi N, et al. A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019. PMID: 31221539. doi:10.1016/j.ejvs.2019.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。